{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-114220","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.751023+00:00","generated_at":"2026-05-17T06:54:53.101197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"enGene Q3 net loss $28.9M; hits LEGEND enrollment target, RMAT designation","bullets":["Cash and marketable securities $224.9M; net loss $28.9M ($0.57/share) vs $14.1M ($0.32/share) YoY.","Achieved target enrollment of 100 patients in LEGEND pivotal cohort; data update expected 4Q 2025.","Detalimogene granted FDA RMAT designation; BLA submission planned for 2H 2026.","Operating expenses $29.9M, up from $16.8M; R&D costs increased $11M on LEGEND manufacturing and clinical costs.","Board appointed Philip Astley-Sparke, William Grossman, Michael Heffernan; promoted Matthew Boyd, Jill Buck, Katherine Chan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-114220","json":"https://secwatch.observer/filing/0000950170-25-114220.json","markdown":"https://secwatch.observer/filing/0000950170-25-114220.md","text":"https://secwatch.observer/filing/0000950170-25-114220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/0000950170-25-114220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017025114220/engn-20250911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:54:53.101197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}